



Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution Form 2020/3/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ANSWER SHEET (Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	10/655,915
Filing Date	09/05/2003
First Named Inventor	Alan D. Attie
Art Unit	1634
Examiner Name	Jehanne Souaya Sitton
Attorney Docket Number	960296 99080

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
JP		WO 03/027228 A2	04/03/2003	Incyte Genomics, Inc.	Abstract only

***EXAMINER:** Initial / reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹** Applicant's unique citation designation number (optional). **²** See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. **⁶** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete If Known	
		Application Number	10/655,915
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	09/05/2003
		First Named Inventor	Alan D. Attie
		Art Unit	1634
		Examiner Name	Jehanne Souaya Sitton
Sheet	2	of	2
		Attorney Docket Number	
		960296.99080	

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JP		Hampe, W, et al., "The genes for the human VPS10 domain-containing receptors are large and contain many small exons," Hum Genet 108:529-536 (2001)	
JP		Hicke, L., "A New Ticket for Entry into Budding Vesicles-Ubiquitin," Cell 106:527530:1-4 September 7, 2001	
JP		Kahn, B.B., "Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance, Cell 92:593-596 (1998) 39/6 90"	
JP		Kahn, C.R., et al., "Genetics of non-insulin-dependent (type-II) diabetes mellitus, Annu. Rev. Med. 47:509-531 (1996)	
JP		Polonsky, K.S., et al, "Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell ..., N Engl J Med 334:777-783 (1996)	
JP		Polonsky, K.S., "The beta-cell in diabetes: from molecular genetics to clinical research, Diabetes 44:705-717 (1995)	
JP		Stoehr, J.P., et al, "Genetic obesity Unmasks Nonlinear Interactions Between Murine Type 2 Diabetes Susceptibility Loci," Diabetes 49:1946-1954 (2000)	
JP		Taylor SI: Deconstructing type 2 diabetes Cell 97:9-12 (1999)	

Examiner Signature	<i>Jehanne Sitton</i>	Date Considered	10/27/06
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.